Plan B to be sold over the counter, protected from generics for three years
As promised, the Food and Drug Administration (FDA) will finally allow the Plan B One-Step morning after pill to be sold to women of all ages, and will protect it from generic competition for the next three years.
July 25, 2013 at 07:56 AM
4 minute read
The original version of this story was published on Law.com
As promised, the Food and Drug Administration (FDA) will finally allow the Plan B One-Step morning after pill to be sold to women of all ages, and will protect it from generic competition for the next three years.
According to Wednesday's decision, generic drug makers can apply to the FDA to sell generic versions of the emergency contraceptive starting in 2016. It's a bit complicated though—the FDA has removed all age restrictions from the sale of Plan B, but any generic versions will only be available to those 17 and older. That means, though both versions will be sold over the counter, anyone younger than 17 will still have to pay the $50 to get brand-name Plan B, while those older can pay about $40 for the generic version. But not until 2016, of course.
The FDA gave in on its legal battle surrounding emergency contraceptives in June, rescinding its claims that the pills were dangerous for young women and agreeing to allow them to be sold without prescriptions to women of any age. However, the cheapest version of Plan B—the two-pill version—will still be tucked away behind counters, and require a prescription for anyone under 17.
Read more at NPR.
For more InsideCounsel coverage of the morning after pill, see below:
As promised, the Food and Drug Administration (FDA) will finally allow the Plan B One-Step morning after pill to be sold to women of all ages, and will protect it from generic competition for the next three years.
According to Wednesday's decision, generic drug makers can apply to the FDA to sell generic versions of the emergency contraceptive starting in 2016. It's a bit complicated though—the FDA has removed all age restrictions from the sale of Plan B, but any generic versions will only be available to those 17 and older. That means, though both versions will be sold over the counter, anyone younger than 17 will still have to pay the $50 to get brand-name Plan B, while those older can pay about $40 for the generic version. But not until 2016, of course.
The FDA gave in on its legal battle surrounding emergency contraceptives in June, rescinding its claims that the pills were dangerous for young women and agreeing to allow them to be sold without prescriptions to women of any age. However, the cheapest version of Plan B—the two-pill version—will still be tucked away behind counters, and require a prescription for anyone under 17.
Read more at NPR.
For more InsideCounsel coverage of the morning after pill, see below:
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
NOT FOR REPRINT
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
You Might Like
View AllCrypto Groups Sue IRS Over Decentralized Finance Reporting Rule
SEC Penalizes Wells Fargo, LPL Financial $900,000 Each for Inaccurate Trading Data
US Reviewer of Foreign Transactions Sees More Political, Policy Influence, Say Observers
Pre-Internet High Court Ruling Hobbling Efforts to Keep Tech Giants from Using Below-Cost Pricing to Bury Rivals
6 minute readTrending Stories
- 1Restoring Trust in the Courts Starts in New York
- 2'Pull Back the Curtain': Ex-NFL Players Seek Discovery in Lawsuit Over League's Disability Plan
- 3Tensions Run High at Final Hearing Before Manhattan Congestion Pricing Takes Effect
- 4Improper Removal to Fed. Court Leads to $100K Bill for Blue Cross Blue Shield
- 5Michael Halpern, Beloved Key West Attorney, Dies at 72
Who Got The Work
Michael G. Bongiorno, Andrew Scott Dulberg and Elizabeth E. Driscoll from Wilmer Cutler Pickering Hale and Dorr have stepped in to represent Symbotic Inc., an A.I.-enabled technology platform that focuses on increasing supply chain efficiency, and other defendants in a pending shareholder derivative lawsuit. The case, filed Oct. 2 in Massachusetts District Court by the Brown Law Firm on behalf of Stephen Austen, accuses certain officers and directors of misleading investors in regard to Symbotic's potential for margin growth by failing to disclose that the company was not equipped to timely deploy its systems or manage expenses through project delays. The case, assigned to U.S. District Judge Nathaniel M. Gorton, is 1:24-cv-12522, Austen v. Cohen et al.
Who Got The Work
Edmund Polubinski and Marie Killmond of Davis Polk & Wardwell have entered appearances for data platform software development company MongoDB and other defendants in a pending shareholder derivative lawsuit. The action, filed Oct. 7 in New York Southern District Court by the Brown Law Firm, accuses the company's directors and/or officers of falsely expressing confidence in the company’s restructuring of its sales incentive plan and downplaying the severity of decreases in its upfront commitments. The case is 1:24-cv-07594, Roy v. Ittycheria et al.
Who Got The Work
Amy O. Bruchs and Kurt F. Ellison of Michael Best & Friedrich have entered appearances for Epic Systems Corp. in a pending employment discrimination lawsuit. The suit was filed Sept. 7 in Wisconsin Western District Court by Levine Eisberner LLC and Siri & Glimstad on behalf of a project manager who claims that he was wrongfully terminated after applying for a religious exemption to the defendant's COVID-19 vaccine mandate. The case, assigned to U.S. Magistrate Judge Anita Marie Boor, is 3:24-cv-00630, Secker, Nathan v. Epic Systems Corporation.
Who Got The Work
David X. Sullivan, Thomas J. Finn and Gregory A. Hall from McCarter & English have entered appearances for Sunrun Installation Services in a pending civil rights lawsuit. The complaint was filed Sept. 4 in Connecticut District Court by attorney Robert M. Berke on behalf of former employee George Edward Steins, who was arrested and charged with employing an unregistered home improvement salesperson. The complaint alleges that had Sunrun informed the Connecticut Department of Consumer Protection that the plaintiff's employment had ended in 2017 and that he no longer held Sunrun's home improvement contractor license, he would not have been hit with charges, which were dismissed in May 2024. The case, assigned to U.S. District Judge Jeffrey A. Meyer, is 3:24-cv-01423, Steins v. Sunrun, Inc. et al.
Who Got The Work
Greenberg Traurig shareholder Joshua L. Raskin has entered an appearance for boohoo.com UK Ltd. in a pending patent infringement lawsuit. The suit, filed Sept. 3 in Texas Eastern District Court by Rozier Hardt McDonough on behalf of Alto Dynamics, asserts five patents related to an online shopping platform. The case, assigned to U.S. District Judge Rodney Gilstrap, is 2:24-cv-00719, Alto Dynamics, LLC v. boohoo.com UK Limited.
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250